Zymeworks ZYME Reportable Segment — Other research and development expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zymeworks's reportable segment — other research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zymeworks's reportable segment — other research and development expense?
- Zymeworks (ZYME) reported reportable segment — other research and development expense of $5.63M in Q1 2026.
- How has Zymeworks's reportable segment — other research and development expense changed year-over-year?
- Zymeworks's reportable segment — other research and development expense increased by 3.1% year-over-year, from $5.46M to $5.63M.
- What is the long-term trend for Zymeworks's reportable segment — other research and development expense?
- Over 3 years (2022 to 2025), Zymeworks's reportable segment — other research and development expense has grown at a 3.6% compound annual growth rate (CAGR), from $19.06M to $21.19M.
- What does reportable segment — other research and development expense mean?
- This metric captures miscellaneous research and development expenditures within the reportable segment that are not categorized as direct personnel or collaboration costs. It reflects the overhead and operational support expenses necessary to sustain the segment's drug discovery and clinical development pipeline.